Compare AMRX & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRX | APGE |
|---|---|---|
| Founded | 2002 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.7B |
| IPO Year | N/A | 2023 |
| Metric | AMRX | APGE |
|---|---|---|
| Price | $13.34 | $78.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $13.25 | ★ $101.89 |
| AVG Volume (30 Days) | ★ 1.7M | 1.0M |
| Earning Date | 10-30-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $2,934,959,000.00 | N/A |
| Revenue This Year | $9.99 | N/A |
| Revenue Next Year | $6.67 | N/A |
| P/E Ratio | $807.28 | ★ N/A |
| Revenue Growth | ★ 9.50 | N/A |
| 52 Week Low | $6.69 | $26.20 |
| 52 Week High | $13.25 | $80.99 |
| Indicator | AMRX | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 68.90 | 65.69 |
| Support Level | $12.33 | $72.56 |
| Resistance Level | $12.99 | $78.34 |
| Average True Range (ATR) | 0.30 | 3.38 |
| MACD | 0.00 | -0.51 |
| Stochastic Oscillator | 92.28 | 74.20 |
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.